Pulmonary fibrosis is a rare, chronic disease that causes scarring in the lungs, making breathing difficult for people who suffer with it.

Pulmonary fibrosis in patients with COVID-19 tends to resolve, while idiopathic pulmonary fibrosis always progresses.

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...